The United Laboratories International Holdings Limited
聯邦制藥國際控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3933)

APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the registration application for Sodium Hyaluronate Eye Drops (specification: 0.3% (5ml: 15mg)) submitted by Zhuhai United Laboratories Co., Ltd, Zhongshan Branch, a wholly-owned subsidiary of the Company, has been approved by China National Medical Products Administration with National Drug Approval Numbers H20269162.

Sodium Hyaluronate Eye Drops are artificial tears indicated for the treatment of corneal and conjunctival epithelial damage associated with endogenous conditions, including Sjögren's syndrome, Stevens-Johnson syndrome, dry eye syndrome and other disorders, as well as exogenous conditions such as post-operative recovery, drug-induced injury, trauma and contact lens wear. The specification of the Company's currently marketed single-dose Sodium Hyaluronate Eye Drops is 0.3% (0.4ml: 1.2mg). The newly approved addition is a multi-dose specification of 0.3% (5ml: 15mg). Currently, Sodium Hyaluronate Eye Drops are listed in the Category B in the National Medical Insurance Drug List (2025 Edition).

The approval will further expand the Company's ophthalmic product portfolio and strengthen its competitiveness in the dry eye treatment market. Looking ahead, the Company will continue to invest in the research and development of new products, strengthen its competitiveness and innovation capabilities in the pharmaceutical industry, which is expected to create greater values for the Company and its shareholders.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 14 July 2026

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit and Ms. Zou Xian Hong as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.